Phase 2 N=100 Randomized Quadruple-blind Treatment

Quercetin in Coronary Artery By-pass Surgery

Coronary Artery Disease

Bottom Line

View on ClinicalTrials.gov: NCT04907253 ↗

Enrolled (actual)

100

Serious AEs

0.0%

Results posted

Apr 2026

Primary outcome: Primary: Quercetin-associated Change in Surgery-associated Inflammation — 9; 3; 87; 109 mg/L

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Quercetin (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Montreal Heart Institute
Primary completion: Dec 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Quercetin-associated Change in Surgery-associated Inflammation	9; 3; 87; 109; 85; 19	—
PRIMARY Quercetin-associated Change in Surgery-associated Marker of Senescence	6.8; 5.5; 6.7; 7.4; 7.5; 7.3	—
SECONDARY Acetylcholine Concentration (nM) Required for EC50 in Endothelium-dependent Relaxation	101; 151	—

Summary

The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.

Eligibility Criteria

Inclusion Criteria

to be able to speak French or English;
to be able to give free and enlighten consent;
be hospitalized and waiting for a cardiac surgery of revascularization;
to have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery.

Exclusion Criteria

to be in a stable state without MI in the last 30 days;
have a cardiac surgery concomitant to the cardiac surgery of revascularization;
have an infection in the last 30 days;
to have renal insufficiency (GFR less than 30);
to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);
to have a known cirrhosis;
to have a past history of breast cancer or other tumors estrogen-dependent;
to be intolerant to flavonoids, niacine or ascorbic acid;
take quinolone;
need for a quinolone during post-op;
not being able to give a free and enlighten consent;
not being able to speak French of English;
take quercetin as a supplement.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04907253). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.